Back to search

Peptide record

TPDB91693

sC18* Antibacterial Anticancer Cell-penetrating Peptides Toxicity standard
12 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB91693
sC18*
Antibacterial Anticancer Cell-penetrating Peptides Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 Peptipedia CPPsite3.0
standard
No
A 12-aa standard natural multi-activity (Antibacterial, Anticancer, Cell-penetrating Peptides, and other sources) peptide sequence curated from AntiBP3, Peptipedia, and CPPsite3.0, with an available 3D structural model.
C-terminal: Amidation
Sequence
GLRKRLRKFRNK-NH2
Physicochemical Analysis
C69H126N28O14
ADCEQHIMPSTWYV
R
1571.94
12.88
7
0
3
+7
4.39
-1.933
65.00
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
1
Residue Composition
number
0
A
4
R
1
N
0
D
0
C
0
E
0
Q
1
G
0
H
0
I
2
L
3
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 4 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 2 K: 3 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
12
C69H126N28O14
1571.94
12.88
+7
4.39
-1.933
Amidation
L
Cationic Amphipathic
Linear
Free
N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)O
Evidence Records 2 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

MCF-7 And HeLa Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L Cationic
Protein derived
5(6)-carboxyfluorescein and Doxorubicin
Vesicles
N50-sC18* and NrTP-sC18* were characterized by an extremely high uptake compared to others
Endocytosis
In vitro
CCCCSBTTBCCCSCC
Evidence 2 Activity

Activity

Cell-penetrating Peptides

Target

HeLa, Hek293 , MCF-7 And Hff-1 Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Amphipathic
Protein derived
5(6)-carboxyfluorescein and Doxorubicin
Cytoplasm
Reduced uptake properties compared to sC18, sC18ΔE and sC18*R,L
Endocytosis
In vitro
CCTTTTTTTTCCSCCCSSSSSCCCSSCCBTTBSCC
Additional Detail Fields 1 fields
CCCCSBTTBCCCSCC CCTTTTTTTTCCSCCCSSSSSCCCSSCCBTTBSCC